Radioactive drug for solid tumors after prior study
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new radioactive drug called MNPR-101-PCTA-177Lu for people with solid tumors who already completed a previous study (MNPR-101-D001). It aims to find the safest and most effective dose by carefully monitoring how your body handles the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have taken part in the earlier MNPR-101-D001 study.
- If you could become pregnant, you need a negative pregnancy test and must use effective birth control during and for 3 months after treatment.
- No chemotherapy, radiation (except short palliative), or immunotherapy within 2 weeks before starting the study drug.
- Your organs (bone marrow, liver, kidneys) must be working well enough—your blood counts, liver enzymes, and kidney function need to be in a healthy range.
- You cannot have had serious side effects from the previous study that lasted more than 30 days or were Grade 4.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.